20196-21-8

Basic information

• Product Name: thiomorpholin-3-one
• Synonyms: thiomorpholin-3-one;THIOMORPHOLINONE;3-Thiomorpholinone
• CAS NO: 20196-21-8
• Molecular Formula: C₄H₇NOS
• Molecular Weight: 117.16948
• EINECS: 243-581-8
• Mol File: 20196-21-8.mol

Chemical Properties

• Melting Point: 87-89 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 349.3 °C at 760 mmHg
• Flash Point: 165 °C
• Appearance: /
• Density: 1.189 g/cm³
• Vapor Pressure: 4.76E-05mmHg at 25°C
• Refractive Index: 1.523
• Storage Temp.: 2-8°C
• PKA: 14.19±0.20(Predicted)
• CAS DataBase Reference: thiomorpholin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: thiomorpholin-3-one(20196-21-8)
• EPA Substance Registry System: thiomorpholin-3-one(20196-21-8)

Safety Data

• Hazardous Substances Data: 20196-21-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Thiomorpholin-3-one is used as a crucial building block for the synthesis of various pharmaceuticals. Its unique structure allows it to be incorporated into the development of new drugs, potentially leading to the discovery of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, thiomorpholin-3-one is employed as a reagent in the production of agrochemicals. Its versatility in chemical reactions enables the synthesis of compounds that can be used in the development of pesticides, herbicides, and other agricultural chemicals, contributing to improved crop protection and yield.
Used in Functional Materials:
Thiomorpholin-3-one is also utilized in the synthesis of functional materials, which are compounds designed to exhibit specific properties for various applications. Its role in creating complex chemical structures makes it a valuable component in the development of materials with tailored characteristics, such as improved conductivity, enhanced stability, or specific reactivity.

InChI:InChI=1/C4H7NOS/c6-4-3-7-2-1-5-4/h1-3H2,(H,5,6)

Upstream product

• 151-56-4 ethyleneimine 
• 623-51-8 ethyl 2-sulfanylacetate 
• 156-57-0 2-mercaptoethylamine hydrochloride 
• 105-39-5 chloroacetic acid ethyl ester 
• 60-23-1 Cysteamine 
• 105-36-2 ethyl bromoacetate 
• 497-25-6 dimethylenecyclourethane 
• 96125-49-4 methyl trans-3-(4-methoxyphenyl)glycidate 

Downstream Products

• 1251834-71-5 4-(2-trifluoromethanesulfonylaminobenzyl)-1,4-thiazinan-3-one 
• 205683-35-8 4-(3,4-Dichloro-phenyl)-thiomorpholin-3-one 
• 67374-14-5 4-(N-methyl-anilinomethyl)-thiomorpholin-3-one 
• 65922-79-4 (5,6-dihydro-2H-[1,4]thiazin-3-yl)-o-tolyl-amine 
• 65922-82-9 (5,6-dihydro-2H-[1,4]thiazin-3-yl)-(3,4,5-trimethoxy-phenyl)-amine 

Relevant articles and documents

Realizing the Trifunctional Potential of Alkyl 4-Chloro-2-diazo-3-oxobutanoates: Convenient Assembly of 6,7-Dihydro-4 H-[1,2,3]triazolo[5,1-c][1,4]thiazine Core

The first example of exploiting the trifunctional character of alkyl 4-chloro-2-diazo-3-oxobutanoates in the reactions with vicinal N, S-bis-nucleophiles leading to the formation of bicyclic 6,7-dihydro-4 H-[1,2,3]triazolo[5,1-c][1,4]thiazines is presente

PHARMACEUTICAL COMPOUNDS

The invention provides compounds of the formula (1) or salts or tautomers thereof; wherein: Q is SO or SO2; n is 1 or 2; R1 is selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; R2 and R3 are independently selected from hydrogen and a C1-6 hydrocarbon group; or R2 and R3 together with the carbon atom to which they are attached form a carbonyl group (C=O), a cyclopropane-1,1-diyl group or a cyclobutane-1,1-diyl group; or R together with R2 forms a C2-4 alkylene linker which is optionally substituted with one or more substituents selected from a C1-4 hydrocarbon group, halogen, hydroxy and amino; R4 and R5 are independently selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; or R4 and R5 together with the carbon atom to which they are attached form a cyclopropane-1,1-diyl group or a cyclobutane-1,1-diyl group; and Ar1 is selected from phenyl, thiophenyl and furanyl,each being optionally substituted. The compounds are useful in medicine, for example in the treatment of diseases, such as cancers.

Construction of tertiary chiral centers by Pd-catalyzed asymmetric allylic alkylation of prochiral enolate equivalents

Abstract The palladium-catalyzed decarboxylative allylic alkylation of enol carbonates derived from lactams and ketones is described. Employing these substrates with an electronically tuned Pd catalyst system trisubstituted chiral centers are produced. These stereocenters have been previously challenging to achieve using Pd complex/chiral P-N ligand systems.

HALOALKYLSULFONANILIDE DERIVATIVE

Novel herbicides are provided. A haloalkylsulfonanilide derivative represented by the formula (1) or an agrochemically acceptable salt thereof: the formula (1): wherein Z is —C(R9)(R10)— or —N(R11)—, A is an oxygen atom, a sulfur atom or —N(R12)—, W is an oxygen atom or a sulfur atom, m is an integer of from 0 to 3, n is an integer of from 0 to 3, m+n is from 1 to 3, R1 is halo C1-C6 alkyl, R2 is a hydrogen atom, C1-C6 alkyl or the like, each of R3 and R4 is independently a hydrogen atom, C1-C6 alkyl or the like, each of R5, R6, R7, R8, R9 and R10 is independently a hydrogen atom, a halogen, C1-C6 alkyl or the like, each of R11 and R12 is a hydrogen atom, C1-C6 alkyl, halo C1-C6 alkyl or the like, and X is independently a hydrogen atom, a halogen, C1-C6 alkyl, or the like.

Base-promoted aminoethylation of thiols with 2-oxazolidinones: A simple synthesis of 2-aminoethyl sulfides

A simple synthesis of 2-aminoethyl sulfides using a base-promoted reaction of 2-oxazolidinones with thiols is described. An application of this method to the synthesis of chiral 2-aminoethyl sulfides and sulfur-containing heterocyclic compounds is also presented.

A Simple Synthesis of β-Amino Sulfides

Thiols reacted with 2-oxazolidinones in the presence of alkoxides to give β-amino sulfides in high yields. The method was applied to the synthesis of 5,6-dihydro-1,4-thiazin-3(2H)-ones.

Cyclic amidine analogs as inhibitors of nitric oxide synthase

Disclosed herein are compounds of Formula I STR1 and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also usful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, mulitple sclerosis, Korsakoff's disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.

Sequential ring expansion and ketene elimination reactions in the novel rhodium(I)-catalyzed carbonylation of thiazolidines

1,3-Thiazolidines react with carbon monoxide, in the presence of catalytic quantities of chloro(1,5-cyclooctadiene)rhodium(I) dimer and potassium iodide, to give thiazolidinones in 56-88% yields. Reaction in the absence of KI afforded the six-membered ring thiazin-3-one. The rhodium(I) complex can catalyze the quantitative conversion of the thiazin-3-one to the thiazolidinone under carbon monoxide, with ketene as the reaction by-product. The conversion of thiazolidines to thiazolidinones involves a novel regiospecific insertion of carbon monoxide into one of two ring carbon-nitrogen bonds, as well as a metal-catalyzed ketene elimination process.

Synthesis and Stereochemistry of rac.-trans-Tetrahydro-6-hydroxy-7-(4-methoxyphenyl)-1,4-thiazepin-5(2H)-one

The base catalyzed reaction of 2-aminoethanethiol (3) with trans-3-(p-methoxyphenyl)glycidate (4) gave a mixture of isomeric lactams 5 and 6, and in addition, a by-product 7.The structures of these isomers were proven by X-ray crystallography.The data revealed that both isomers adopt the chair conformation in the solid state and the size of the heterocyclic ring in compound 5 is a six- and in compound 6 is a seven-membered ring.